Researchers have uncovered a surprising new mechanism behind memory loss in Alzheimer’s disease, identifying dopamine deficiency as a major contributor to cognitive decline. The discovery could open the door to new treatment approaches aimed at restoring memory in patients suffering from the disease.
The study was led by scientists at Tohoku University in collaboration with researchers from the University of California, Irvine. Their findings were published in the journal Nature Neuroscience on April 23, 2026.
For years, Alzheimer’s research has mainly focused on amyloid-beta plaques and tau proteins, which are hallmarks of the disease. However, despite decades of research, treatments targeting these proteins have had limited success in reversing memory impairment. The new research suggests dopamine signaling in the brain may play a much more important role than previously believed.
The scientists focused on the entorhinal cortex, a region of the brain essential for memory formation and communication with the hippocampus. Using a mouse model of Alzheimer’s disease, the team discovered that dopamine levels in this area dropped to less than 20% of normal levels. This severe reduction was linked to major problems in associative memory and learning ability.
During experiments, mice with reduced dopamine struggled with odor-based learning tasks that healthy mice could complete successfully. Further analysis revealed that neurons in the affected brain region were unable to properly respond to memory-related signals.
The breakthrough came when researchers attempted to restore dopamine activity. By increasing dopamine levels in the entorhinal cortex using optogenetic methods, they successfully recovered memory formation in the mice. In another experiment, treatment with Levodopa, a drug commonly prescribed for Parkinson’s disease, also improved neural activity and restored memory performance.
Lead researcher Kei Igarashi said the findings were unexpected and could change the direction of Alzheimer’s treatment research worldwide. According to the researchers, therapies designed to restore dopamine signaling may eventually help slow, prevent, or even reverse cognitive decline in some patients.
Although the findings are still based on animal studies, the research provides fresh hope for millions of people affected by Alzheimer’s disease globally. Scientists believe dopamine-based therapies could become a promising new strategy in future clinical research.
